FDA has granted an emergency use authorization to Quest Diagnostics’ Focus Diagnostics Business for its test to detect the 2009 H1N1 influenza virus, a strain of influenza A
Quark has releases the data suggesting that QPI-1007 prevents progressive retinal ganglion cell (RGC) loss in an increased ocular pressure (IOP) rat model of glaucoma. The experiments done
Ceragenix Pharmaceuticals has signed an exclusive distribution and supply agreement with Megapharm, an Israeli company. The deal is to commercialize EpiCeram, a topical cream for treating atopic dermatitis
Prolor has entered into an evaluation and option agreement with Yeda. Under the terms of the agreement, Prolor may obtain from Yeda a license to develop a number
NeoPharm has reported a net loss of $1.9 million for the second quarter ended June 30, 2009, as compared to a net loss of $2 million for the
Celsion’s global phase III ThermoDox trial for the treatment of primary liver cancer will be extended to Japan by Yakult Honsha’s expertise. The latter is the exclusive licensor
Teleflex Incorporated has reported a decrease in revenues from continuing operations by 14% to $483.1 million in the second quarter of 2009, as compared to $559.7 million in
Phase Forward has acquired privately-held Maaguzi, a provider of Web-based, electronic patient reported outcomes (ePRO) and late phase solutions, for $11 million. This acquisition extends Phase Forward’s integrated
Wyeth (WKK), ASKA and Takeda have reported changes to the Japanese distribution, sales and promotion for WKK’s transdermal absorption-type analgesic and anti-inflammatory agent, SELTOUCH Pap 70, 140 (SELTOUCH).
Eli Lilly and BioMS have reported that dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (EDSS). The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.